VTGN
VistaGen Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.24
−1.38%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.5M | 1.3M | 486.0K | 1.1M | (227.0K) |
| Cost of Revenue | 386.0K | — | — | — | — |
| Gross Profit | 2.1M | 1.3M | 486.0K | 1.1M | (227.0K) |
| Operating Expenses | |||||
| R&D Expense | 54.0M | 55.0M | 39.4M | 20.0M | 44.4M |
| SG&A Expense | 17.9M | 18.4M | 17.1M | 14.1M | 14.7M |
| General & Admin Expense | 17.9M | 18.4M | 17.1M | 14.1M | 14.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (197.0K) | — | — | — | — |
| Total Operating Expenses | 71.8M | 73.4M | 56.5M | 34.1M | 59.0M |
| Cost and Expenses | 72.2M | 73.4M | 56.5M | 34.1M | 59.0M |
| Operating Income (EBIT) | (69.7M) | (72.1M) | (56.0M) | (33.0M) | (59.3M) |
| Non-Operating | |||||
| Interest Income | 2.0M | 2.4M | 4.6M | 3.4M | 49.0K |
| Interest Expense | — | — | — | — | 23.0K |
| Net Interest Income | 2.0M | 2.4M | 4.6M | 3.4M | 26.0K |
| Other Non-Op Income/Expense | 2.1M | 2.4M | 4.6M | 3.7M | 26.0K |
| Non-Operating Income (excl Interest) | (1.6M) | — | (4.6M) | (3.7M) | 28.2K |
| EBT (Pre-Tax Income) | (67.6M) | (69.7M) | (51.4M) | (29.4M) | (59.2M) |
| Income Tax Expense | 7.0K | 7.0K | 7.0K | 4.0K | 6.0K |
| Bottom Line | |||||
| Net Income | (67.6M) | (69.7M) | (51.4M) | (29.4M) | (59.2M) |
| Earnings from Cont. Ops | (67.6M) | (69.7M) | (51.4M) | (29.4M) | (59.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (67.6M) | (69.7M) | (51.4M) | (29.4M) | (59.2M) |
| Per Share | |||||
| Basic EPS | ($1.70) | ($1.83) | ($1.67) | ($1.52) | ($8.51) |
| Diluted EPS | ($1.70) | ($1.83) | ($1.67) | ($1.52) | ($8.51) |
| Revenue Per Share | $0.06 | $0.03 | $0.02 | $0.05 | ($0.03) |
| Shares | |||||
| Basic Shares Outstanding | 43.0M | 38.1M | 30.9M | 19.4M | 7.0M |
| Diluted Shares Outstanding | 43.0M | 38.1M | 30.9M | 19.4M | 7.0M |
| Profitability Metrics | |||||
| EBITDA | (67.3M) | (71.4M) | (50.8M) | (28.8M) | (58.7M) |
| D&A | 761.0K | 733.0K | 635.0K | 568.0K | 532.0K |
| EBIT | (68.1M) | (72.1M) | (51.4M) | (29.4M) | (59.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026